VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
VERAXA Biotech has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
VERAXA Biotech's investors include Lincoln Park Capital Fund.
VERAXA Biotech is headquartered in Heidelberg, Germany.
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
VERAXA Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VERAXA Biotech — Funding & Investors." VCBacked, June 10, 2026, https://www.vcbacked.co/company/veraxa-biotech. Accessed November 13, 2026.
VCBacked. (2026). VERAXA Biotech — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/veraxa-biotech
{{cite web |title=VERAXA Biotech — Funding & Investors |url=https://www.vcbacked.co/company/veraxa-biotech |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at VERAXA Biotech? Request a listing update